Journal article
Comparison of Prediction Models for Lynch Syndrome among Individuals with Colorectal Cancer
F Kastrinos, RP Ojha, C Leenen, C Alvero, RC Mercado, J Balmaña, I Valenzuela, F Balaguer, R Green, NM Lindor, SN Thibodeau, P Newcomb, AK Win, M Jenkins, DD Buchanan, L Bertario, P Sala, H Hampel, S Syngal, EW Steyerberg
Journal of the National Cancer Institute | OXFORD UNIV PRESS INC | Published : 2016
DOI: 10.1093/jnci/djv308
Abstract
Background: Recent guidelines recommend the Lynch Syndrome prediction models MMRPredict, MMRPro, and PREMM1,2,6 for the identification of MMR gene mutation carriers. We compared the predictive performance and clinical usefulness of these prediction models to identify mutation carriers. Methods: Pedigree data from CRC patients in 11 North American, European, and Australian cohorts (6 clinic- and 5 population-based sites) were used to calculate predicted probabilities of pathogenic MLH1, MSH2, or MSH6 gene mutations by each model and gene-specific predictions by MMRPro and PREMM1,2,6. We examined discrimination with area under the receiver operating characteristic curve (AUC), calibration with..
View full abstractRelated Projects (1)
Grants
Awarded by National Cancer Institute
Funding Acknowledgements
This work was supported by the National Cancer Institute (K07 CA151769-02 to FK; R01 CA132829 and K24 CA113433 to SS) and through cooperative agreements with members of the Colon Cancer Family Registry and PIs including Australasian Colorectal Cancer Family Registry (U01 CA097735), the University of Southern California (USC) Colorectal Cancer Family Registry (U01 CA074799), the Mayo Clinic Cooperative Family Registry for Colon Cancer Studies (U01 CA074800), the Ontario Registry for Studies of Familial Colorectal Cancer (U01 CA074783), the Seattle Colorectal Cancer Family Registry (U01 CA074794), and the University of Hawaii Colorectal Cancer Family Registry (U01 CA074806). The content of this manuscript does not necessarily reflect the views or policies of the National Cancer Institute or any of the collaborating centers in the Colon Cancer Family Registry (CCFR), nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government or the CCFR.